Metformin treatment in patients with type 2 diabetes who have historical contraindications to the drug's use is associated with improved clinical outcomes, new research shows.

The US Food and Drug Administration (FDA) has removed the final remaining restrictions placed on the use of rosiglitazone.

In a response to mounting evidence, the US Food and Drug Administration (FDA) announced that the diabetes drug metformin can be used safely in patients with mild and, in some cases, moderate kidney impairment after decades of warning against it. This means that a generic and therefore cheap effective agent for type 2 diabetes should be more widely available for use, as many patients with diabetes also have some form of renal impairment.

The diabetes drug metformin is sparking new interest as a cancer fighter.

Among obese children without diabetes, metformin improves body mass index (BMI) and inflammatory and cardiovascular-related obesity parameters in prepubertal children but not in pubertal children, a new study shows.

Peripheral Neuropathy Patients Who Take Diabetes Drug May Have Vitamin B12 Deficiency

In new research from the Mayo Clinic, ovarian cancer patients who took the drug metformin survived longer than patients who did not take it.

The European Medicines Agency (EMA) has announced that metformin-containing medicines can now be used in patients with moderately reduced kidney function — defined as a glomerular filtration rate (GFR) of 30 to 59 mL/min — for the treatment of type 2 diabetes.

The US Food and Drug Administration (FDA) has approved a once-daily oral combination of linagliptin and metformin hydrochloride (Jentadueto XR, Boehringer Ingelheim and Eli Lilly & Co) for treating adults with type 2 diabetes.

A new retrospective study indicates that, in type 2 diabetes, treatment with insulin is safer when it is used together with metformin.

According to a new study, the drug metformin should be considered as a first choice for blood sugar control in people with type 2 diabetes.

Concerns that the diabetes drugs Avandia and Actos raise the risk for heart failure led the FDA to require label changes warning of the potential risk two years ago.

In light of metformin, older people with type 2 diabetes who take an older class of oral diabetes drugs called sulfonylureas may have a higher risk of developing heart problems.

Long-term treatment with the type 2 diabetes drug metformin improves health and longevity of male mice when started at middle age, reports an international team of scientists led by researchers at the National Institute on Aging (NIA).

The FDA today announced it is requiring the removal of certain restrictions on prescribing and use of the diabetes drug Avandia (rosiglitazone) to reflect new information regarding the cardiovascular risk of the medicine.

Metformin plus Avandia is better than metformin alone for kids and teens with type 2 diabetes, according to a new government study.

The US Food and Drug Administration (FDA) has approved a new type 2 diabetes drug that combines the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin with metformin hydrochloride (Synjardy, Boehringer Ingelheim and Eli Lilly), according to a news release from the two companies.

Updates to the US Food and Drug Administration's (FDA's) watch list include 27 drugs or drug classes for which there is new safety information or possible signs of serious risk.

The National Institutes of Health is looking for volunteers to take part in a study to compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes.

In patients with prediabetes determined to be at high risk of progression to diabetes through oral glucose testing, treatment with a triple regimen of medications significantly reduced the likelihood of progression to type 2 diabetes compared with lifestyle modifications alone, according to new research.

The National Institutes of Health is looking for volunteers to take part in one of three clinical trials to improve and preserve the production of insulin in people with prediabetes or recently diagnosed type 2 diabetes. The project is called the Restoring Insulin Secretion study (RISE).

SGLT2 inhibitors, a new class of diabetes drugs, have an interesting side effect: weight loss.

Read about FDA's increased heart failure risk warnings on Type 2 diabetes drugs on RxList.

A new oral diabetes drug is expected to arrive on pharmacy shelves in the U.S. this week.

A US Food and Drug Administration (FDA) advisory committee urged approval — though not without some reservations — of a new injectable knonwn generically as iGlarLixi that combines fixed doses of insulin glargine (Lantus, Sanofi) with lixisenatide (Lyxumia, Sanofi), a glucagon-like peptide 1 (GLP-1) receptor agonist still pending FDA approval for type 2 diabetes.

The US Food and Drug Administration (FDA) has approved two new competing combination products containing fixed doses of glucagonlike-peptide 1 (GLP-1) receptor agonists and long-acting insulins, from Sanofi and Novo Nordisk respectively, for the treatment of adults with type 2 diabetes.

A combination of pioglitazone and the glucagonlike peptide 1 (GLP-1) agonist exenatide (Bydureon, AstraZeneca) may represent an effective and safe alternative to insulin for the treatment of type 2 diabetes in patients who are poorly controlled despite use of both metformin and a sulfonylurea.

The US Food and Drug Administration has approved the empagliflozin/linagliptin combination Glyxambi (Boehringer Ingelheim/Eli Lilly) as adjunctive treatment to diet and exercise for adults with type 2 diabetes.

Just over a month after Novo Nordisk announced positive top-line results for liraglutide (Victoza, Novo Nordisk), showing that it significantly reduced the risk of major adverse cardiovascular events in the LEADER Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial, the company has announced another positive study of a similar agent — both are glucagonlike peptide-1 (GLP-1) agonists for the treatment of type 2 diabetes; this time it is a once-weekly product called semaglutide, which is not yet approved anywhere.

Diabetic patients who took Victoza achieved better blood sugar control and lost more weight than patients who took the widely prescribed oral drug Januvia.

The US Food and Drug Administration (FDA) has issued a new alert about the potential for increased risk for heart failure in patients taking the type 2 diabetes drugs saxagliptin (Onglyza, AstraZeneca Pharmaceuticals LP) and alogliptin (Nesina, Takeda Pharmaceuticals).

Therapeutic intermittent fasting may help eliminate the need for insulin and other glucose-lowering medications in patients with type 2 diabetes, a new case series suggests.

Type 2 diabetes is rising rapidly among children and teens because of soaring obesity rates.

According to a new study, inhaled insulin proved to be as effective at lowering blood sugar levels as insulin injections, and with minimal side effects, among patients with uncontrolled type 2 diabetes.

An oral basal insulin formulation has produced glycemic control equivalent to that of injected insulin glargine in insulin-naïve type 2 diabetes patients.

The diabetes drug Actos (pioglitazone) is under FDA review due to its association with bladder cancer.

Higher insulin doses do not raise the risks for mortality or major adverse cardiovascular events (MACE) in patients with type 2 diabetes, new research indicates, after careful adjustment for potential confounders.